For Immediate Release

ASX Announcement

7 April 2026
Melbourne, Australia

U.S. SECTION 232 TARIFFS ON PHARMACEUTICALS

CSL Limited (ASX:CSL; USOTC:CSLLY) notes the announcement by the United States Administration on 2 April 2026 that it intends to impose tariffs on pharmaceutical products imported to the United States (U.S.) using a proclamation under section 232 of the Trade Expansion Act (Proclamation).

CSL is working through the details of the Proclamation, but the initial view is that most of CSL's U.S. product sales will not be subject to tariffs.

CSL is pleased the U.S. Administration has recognised the unique nature of plasma-derived therapies under the Proclamation. This is consistent with the longstanding approach of special policy accommodations to ensure patient access to these life-saving therapies.

CSL's U.S. plasma therapies are derived entirely from U.S. sourced plasma. CSL continues to invest in manufacturing and job creation in the U.S., recently announcing plans to spend $1.5 billion to expand its plasma therapy manufacturing capabilities in Illinois.

CSL Seqirus' primary product sold in the U.S. is Fluad®. This is manufactured in the United Kingdom where the tariff rate is presently 10%. Current expectations are that this tariff will reduce to 0%.

The effective date for any tariff impacts is 29 September 2026.

Authorised for lodgement by:

Fiona Mead

Company Secretary

Investor Relations

Michelle Rees
Head, Investor Relations
CSL Limited
P: +61 410 600 745
E: michelle.rees@csl.com.au

Media Relations

Brett Foley
Director, Corporate Communications
CSL Limited
P: +61 461 464 708
E: brett.foley@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000